<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976595</url>
  </required_header>
  <id_info>
    <org_study_id>NAT-2020-01</org_study_id>
    <nct_id>NCT04976595</nct_id>
  </id_info>
  <brief_title>A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel</brief_title>
  <official_title>A 24-hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Treated With Natesto Nasal Testosterone Gel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerus Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerus Pharmaceuticals Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the change in 24-hour ambulatory blood pressure&#xD;
      monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone&#xD;
      therapy with Natesto.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 24-Hour Systolic Blood Pressure (SBP) At Day 120</measure>
    <time_frame>Baseline (Day 0) and Day 120</time_frame>
    <description>The change from baseline (Day 0) in 24-hour SBP after 120 days of Natesto treatment will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-hour Average Mean Arterial Pressure (MAP)</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-hour Average Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-hour Average Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-hour Average Pulse Pressure</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-hour Average Heart Rate</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hourly Average Mean Arterial Pressure (MAP)</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hourly Average Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hourly Average Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hourly Average Pulse Pressure</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hourly Average Heart Rate</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Anti-hypertensive Medications</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Dose Increases in Anti-hypertensive Medications</measure>
    <time_frame>Baseline (Day 0) up to Day 120</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Natesto</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will administer Natesto, gel, intranasally, three times daily up to Day 120. A multiple-dose dispenser will be used for gel deposition into the nasal cavity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natesto</intervention_name>
    <description>Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily.</description>
    <arm_group_label>Natesto</arm_group_label>
    <other_name>Testosterone Nasal Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily sign and date the study consent form(s) which have been approved by an&#xD;
             Institutional Review Board (IRB). Written consent must be obtained prior to the&#xD;
             initiation of any study procedures.&#xD;
&#xD;
          -  Male between 18 and 80 years of age, inclusive, with documented onset of hypogonadism&#xD;
             prior to age 65.&#xD;
&#xD;
          -  Serum total testosterone &lt; 300 ng/dL based on 2 consecutive blood samples obtained no&#xD;
             greater than 1-4 weeks apart between 6 and 10 AM following an appropriate washout of&#xD;
             current androgen replacement therapy if not testosterone naive. Historical values from&#xD;
             the past 6 months may be used.&#xD;
&#xD;
          -  Testosterone Therapy naive, OR off any testosterone therapy for at least 4 months OR&#xD;
             agree to a 4-month washout of current testosterone therapy prior to entry at Visit 1.&#xD;
&#xD;
          -  Average office blood pressure measurement &lt;140 millimetre of mercury (mmHg) SBP -AND-&#xD;
             &lt;90 mmHg DBP.&#xD;
&#xD;
          -  If the participant is on an antihypertensive regimen, he has been on it for at least 4&#xD;
             weeks.&#xD;
&#xD;
          -  Judged to be in good general health as determined by the principal investigator based&#xD;
             upon the results of a medical history, physical examination, vital signs, laboratory&#xD;
             profile and a 12-lead electrocardiogram (ECG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of significant sensitivity or allergy to androgens, castor oil or product&#xD;
             excipients.&#xD;
&#xD;
          -  Clinically significant findings in the pre-study examinations including abnormal&#xD;
             breast examination requiring follow-up, an abnormal ECG.&#xD;
&#xD;
          -  Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or&#xD;
             International Prostate Symptom Score (I-PSS) score &gt; 19 points.&#xD;
&#xD;
          -  Body mass index (BMI) â‰¥ 35 kg/m^2.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory value, in the opinion of the investigator,&#xD;
             in serum chemistry, hematology, or urinalysis including but not limited to:&#xD;
&#xD;
               -  Prostate specific antigen (PSA) &gt; 4 ng/mL&#xD;
&#xD;
               -  Hematocrit &lt; 35% or &gt; 50%&#xD;
&#xD;
               -  Baseline hemoglobin &gt; 16 g/dL&#xD;
&#xD;
               -  Hemoglobin A1C (HbA1C) &gt; 9.0%&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) &lt;45&#xD;
&#xD;
          -  History of seizures or convulsions, including febrile, alcohol or drug withdrawal&#xD;
             seizures.&#xD;
&#xD;
          -  History of any clinically significant illness, infection, or surgical procedure within&#xD;
             4 weeks prior to study drug administration except for diabetes, or renal disease.&#xD;
&#xD;
          -  History of stroke or myocardial infarction within the past 5 years.&#xD;
&#xD;
          -  History of, or current or suspected, prostate or breast cancer.&#xD;
&#xD;
          -  History of diagnosed, severe, untreated, obstructive sleep apnea.&#xD;
&#xD;
          -  History of abuse of alcohol or any drug substance in the opinion of the investigator&#xD;
             within the previous 2 years.&#xD;
&#xD;
          -  Currently using tobacco, e-cigarettes or other nicotine containing products.&#xD;
&#xD;
          -  History of nasal disorders such as nasal surgery; nasal trauma resulting in nasal&#xD;
             fracture within the previous 6 months or nasal fracture that caused a deviated&#xD;
             anterior nasal septum; or sinus surgery or sinus disease.&#xD;
&#xD;
          -  Receipt of any investigational product within 4 weeks of study start.&#xD;
&#xD;
          -  Inability to understand and provide written informed consent for the study.&#xD;
&#xD;
          -  Considered by the investigator or the sponsor-designated physician, for any reason, as&#xD;
             an unsuitable candidate to receive Natesto.&#xD;
&#xD;
          -  Participants working night-shifts.&#xD;
&#xD;
          -  Participants performing strenuous manual labor while wearing the ABPM monitor.&#xD;
&#xD;
          -  Participants with chronic atrial fibrillation (interferes with the ability to obtain&#xD;
             precise ambulatory recordings).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. C. Sorli Chief Medical Officer</last_name>
    <phone>+1 289 326 5762</phone>
    <email>csorli@aceruspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Horizon Clinical Research Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85295</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eclipse Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valley Clinical Trials</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Rockies</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Horizon Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research of Indiana</name>
      <address>
        <city>Elwood</city>
        <state>Indiana</state>
        <zip>46036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research GI, LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Biomedical Research of America</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Urology Group</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08837</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ProHEALTH Care Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Research Foundation for the State University of New York at Buffalo</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Warren Alpert School of Medicine Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Austin Urology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Coastal Bend Clinical Research</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Prime Revival Research Institute</name>
      <address>
        <city>Flower Mound</city>
        <state>Texas</state>
        <zip>76201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypogonadism</keyword>
  <keyword>Gonadal Disorders</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Hormones</keyword>
  <keyword>Androgens</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Ambulatory Blood Pressure Monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

